Genetron Health announces partnership with NeoGenomics

Genetron Holdings Limited, or Genetron Health, a Nasdaq-listed Chinese precision oncology platform company that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced on Monday its strategic partnership with NeoGenomics Inc, a US-based Nasdaq-listed company that specializes in cancer genetic testing and information services.

The two parties will partner globally to provide select harmonized clinical trials, global translational research for pharmaceutical groups and technology platform providers that need a China arm for global or China focused trials.

Additionally, NeoGenomics will support Genetron Health on trials outside of China based in any of the following locations: the US, Asia-Pacific region including Japan, Europe, Middle East and/or Africa. This will encompass developing and operating clinical trials for both oncology drugs and their corresponding companion diagnostics products.

The partnership will combine the two companies' strengths to leverage a rich, diverse core technology platform and product pipeline that covers molecular detection, histopathologic diagnosis, multifluorescence immunohistochemistry, flow cytometry, immunoassays, in situ hybridization, and cell genetic mapping, Genetron Health said in a press release.